Eczema Therapeutics Market to Grow with a CAGR of 7.46% through 2028

Medical breakthroughs, rising patient awareness, and evolving treatment options are expected to drive the Global Eczema Therapeutics Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “Eczema Therapeutics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Eczema Therapeutics Market stood at USD 13.25 billion in 2022 and is anticipated to grow with a CAGR of 7.46% in the forecast period, 2024-2028. This can be attributed to government initiatives and healthcare policies. Government initiatives aimed at improving dermatological care and healthcare policies that support the affordability of eczema therapeutics have played a role in market growth. Access to insurance coverage and reimbursement for eczema treatments has made these therapies more accessible to a broader patient population.

Furthermore, the eczema therapeutics market will continue to expand globally, with emerging economies experiencing a growing burden of eczema cases. Pharmaceutical companies and healthcare systems will increasingly focus on providing access to effective treatments in these regions, reducing global disparities in eczema care.

The market for eczema treatment is set to thrive due to several key factors. Firstly, the increasing prevalence of eczema, coupled with a robust pipeline of innovative therapies and the emergence of biologics, is expected to drive market growth in the foreseeable future. According to a study published in the Acta Derm Venereologica Journal in 2020, the diagnosed prevalence of atopic dermatitis varies globally, ranging from 17.1% in European adults to 10.2% in Asian adults, and 22.6% and 0.96% respectively in children. This condition imposes a significant economic and social burden, ranking as one of the most prominent skin disorders. The COVID-19 pandemic has further exacerbated the situation, with increased handwashing leading to dry, cracked skin, and a surge in hand eczema due to frequent use of oil-stripping soaps and hand sanitizers. This unmet need creates an opportunity for market players to develop moisturizer-based creams and ointments to cater to this growing segment.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Eczema Therapeutics Market.”

In response to the lucrative eczema market, companies are investing heavily in research and development to introduce innovative products. The rising number of drugs entering late-stage clinical trials with promising results is expected to boost revenue for major companies in the coming years. For example, Galderma reported positive phase 2b results for Nemolizumab in uncontrolled atopic dermatitis patients in April 2021, and Pfizer demonstrated the non-inferiority of its under-development drug Abrocitinib compared to the existing treatment Dupixent by Sanofi in March 2021. Additionally, there is a significant unmet need for oral medications among atopic dermatitis patients, which could be addressed by the launch of Abrocitinib, a Janus kinase 1 (JAK1) inhibitor. Cara Therapeutics is also developing Korsuva, a phase 2 oral drug for pruritus associated with atopic dermatitis.

Furthermore, the market is poised for growth with the increasing approval of new products and the emergence of biologics for eczema management. Notably, in June 2022, Sanofi received U.S. FDA approval for Dupixent (dupilumab) for children aged 6 months to 5 years with atopic dermatitis, while AbbVie Inc. secured U.S. FDA approval for RINVOQ (upadacitinib) in January 2022, aimed at managing severe atopic dermatitis in individuals over 12 years of age and adults who have not responded to prior treatments. RINVOQ is recommended for patients who have not benefited from previous injections and pills. These developments are expected to further fuel market growth in the eczema therapeutics sector.

The Global Eczema Therapeutics Market is segmented into treatment, distribution channel, regional distribution, and company.

Based on its treatment, Immunomodulators are poised to dominate the Global Eczema Therapeutics Market due to their unique and highly effective approach in managing this chronic skin condition. Eczema, characterized by inflamed and itchy skin, is primarily driven by an overactive immune response. Immunomodulators work by precisely targeting the immune system, regulating its activity, and reducing inflammation at the cellular level. This precision in treatment not only provides relief from eczema symptoms but also minimizes the potential side effects associated with broader immunosuppressive therapies. Furthermore, as patients increasingly seek alternatives to topical steroids, which can have adverse effects with prolonged use, the demand for immunomodulators is on the rise. With ongoing research and development, coupled with a growing awareness of the benefits of these therapies, it is expected that immunomodulators will continue to gain prominence in the eczema therapeutics market, offering hope for millions of individuals seeking effective and safer treatment options.

Based on distribution channel, Hospitals and clinics are positioned to dominate the Global Eczema Therapeutics Market due to their critical role as healthcare providers and centers for comprehensive patient care. Eczema, a complex and often chronic skin condition, necessitates a multifaceted approach to treatment. Hospitals and clinics offer a range of specialized services, including dermatology departments, which are essential in diagnosing and managing eczema effectively. They provide access to dermatologists and allergists who can accurately diagnose the condition and develop personalized treatment plans tailored to each patient's specific needs. Additionally, these healthcare facilities are equipped to administer various treatment modalities, such as immunomodulators, phototherapy, and advanced topical therapies, which often require medical supervision. As eczema cases continue to rise globally, the expertise and resources available in hospitals and clinics make them central hubs for delivering comprehensive eczema care, thus cementing their dominance in the eczema therapeutics market.

Major companies operating in Global Eczema Therapeutics Market are:

• Sanofi SA
• Encore Dermatology Inc.
• AbbVie Inc.
• F Hoffmann-La Roche AG
• Novartis AG
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• GSK PLC
• AstraZeneca PLC
• Pfizer Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The Global Eczema Therapeutics Market is undergoing a transformation, driven by innovation and a growing understanding of the condition. Emerging trends in biologic therapies, personalized medicine, digital health, and holistic patient care are set to reshape the landscape of eczema treatment. As these trends continue to evolve, there is reason to be optimistic that the future will bring improved outcomes and better quality of life for individuals living with eczema,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Eczema Therapeutics Market By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors), By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Eczema Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Eczema Therapeutics Market.